Montana Healthcare Programs
Drug Prior Authorization Coverage Criteria

Oxervate™ (cenegermin-bkbj)

Review Criteria

Member must meet all the following criteria:

- Diagnosis of stage II/III neurotrophic keratosis (NK) required
- Medication must be prescribed by or in consultation with an ophthalmologist
- Patient must be > 2 years of age
- Approval granted only for 8-week duration (no evidence of benefit beyond 8 weeks)

Limitations:

- Maximum daily dose is 1 vial per day per eye affected